U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07066995) titled 'Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer' on July 04.
Brief Summary: Autologous T-cells engineered to express CARs targeting Mesothelin and Claudin18.2, for Unresectable locally advanced or metastatic pancreatic adenocarcinoma (Pancreatic Ductal Adenocarcinoma, PDAC), administered as two separate sequential infusions following lymphodepleting chemotherapy
Study Start Date: April 29
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Pancreatic Carcinoma
Pancreatic Cancer Non-resectable
Pancreatic Cancer Stage IV
Intervention:
BIOLOGICAL: Mesothelin and Claudin 18.2 CAR-T cells
Th...